Neurology Central

Dynorphin-based gene therapy demonstrates long-term suppression of seizures


A new therapeutic concept for the treatment of temporal lobe epilepsy has been developed by researchers from Charité – Universitätsmedizin Berlin (Germany) and the Medical University of Innsbruck (Austria). The treatment, which utilizes a dynorphin-based gene therapy, has been reported to suppress seizures at their site of origin and on demand. The results for this study have been published in EMBO Molecular Medicine.

Temporal lobe epilepsy is the most common form of epilepsy and can lead to memory problems, in addition to impaired learning and emotional control. Current medications that are used to treat individuals with temporal lobe epilepsy are often unable to adequately control the disorder and are associated with severe side effects. At present, the only alternative treatment available includes surgical removal of the temporal lobe.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.